OHDSI MEETINGS THIS WEEK
The Book of OHDSI working group meeting - Tuesday at 11am EThttps://columbiauniversity.zoom.us/j/258043190
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=96139.930901412523321531221112212141232121131213113112112121536
CDM & Vocabulary working group meeting - Tuesday at 1pm EThttps://jjconferencing.webex.com/jjconferencing/j.php?MTID=mbaf813b4a880801647e617d06da04ddf
CDM-Genomics WG meeting - Wendesday at 11am EThttps://abmi.webex.com/webappng/sites/abmi/meeting/info/116787143000498361?MTID=m2747af107665e0586909629968cc2260
ATLAS working group meeting - Wednesday at 10am EThttps://jjconferencing.webex.com/jjconferencing/j.php?MTID=mca074ae1ff6eb7d80245d36b59188c80
Patient-Level Prediction working group meeting - Wednesday at 12pmEThttps://global.gotomeeting.com/join/972917661
ACHILLES working group meeting - Wednesday at 2pm EThttps://columbiauniversity-373.my.webex.com/mw3300/mywebex/default.do?service=1&siteurl=columbiauniversity-373.my&nomenu=true&main_url=%2Fmc3300%2Fe.do%3Fsiteurl%3Dcolumbiauniversity-373.my%26AT%3DMI%26EventID%3D789489347%26UID%3D546683597%26Host%3DQUhTSwAAAAQ088ZwhcIU1Pt5vu-xn11lvwlVLkHd6aFBTkKx7yvIwtHfnTZ_7KK0FTmcm1i5V6ptAZwPOLWFILsjuEwIoBDE0%26FrameSet%3D2%26MTID%3Dmecc98516ea6b92858b7fe2adc20d6897
NLP working group - Wednesday at 2pm EThttps://global.gotomeeting.com/join/707196421
China WG meeting - Friday at 10pm EThttps://global.gotomeeting.com/join/721873621
GIS working group meeting - Monday (May 13th) at 10am EThttps://tufts.webex.com/webappng/sites/tufts/meeting/info/126710310532817398?MTID=m243d8e9a9c6c2d42d5182aeb5d30efdb
You can find a full list of upcoming OHDSI meetings here:https://docs.google.com/document/d/1X0oa9R-V8cwpF1WQZDJOqcXZguPKRiCZ6XrQ2zXMiuQ/edit
ANNOUNCEMENTS
Looking for presenters for upcoming OHDSI community calls We are looking for collaborators to share their work on upcoming OHDSI calls. If you are interested in presenting on an upcoming OHDSI call please email me at beaton@ohdsi.org
2019 OHDSI F2F - REGISTRATION OPEN! Register now for the 2019 OHDSI F2F, set to take place on June 3-4th 2019 at Case Western Reserve University in Cleveland, OH. For more details check out the event page: https://www.ohdsi.org/events/2019-ohdsi-face-to-face/
THEMIS F2F - This year’s F2F will take place next week, May 14-15th at the University of Colorado. For me details check out our event page: https://www.ohdsi.org/events/themis-f2f/
2019 OHDSI Symposium - REGISTRATION NOW! - Register now for the 2019 OHDSI Symposium, set to take place Monday, September 16th at the Bethesda North Marriott in Bethesda, MD. A separate registration will open in May for tutorials. https://www.ohdsi.org/symposium-registration-3/
2019 OHDSI Symposium - CALL FOR PARTICIPATION - The symposium planning committee is now accepting abstract submissions for poster presentations, software demonstrations and oral presentations. For more details, check out our collaborator page: https://www.ohdsi.org/collaborator-showcase-2/ https://www.ohdsi.org/collaborator-showcase-submissions/
2019 OHDSI Symposium - Creative Submissions - In addition to scientific submissions, we’re also inviting collaborators to showcase their special talents! For more details about creative submissions is available here: https://www.ohdsi.org/creative-submissions/
Words are loaded pistols.
COMMUNITY PUBLICATIONS
Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
HS Park, D Yoon, HY Lee, GY Ban, S Wan Yau Ming, JLZ Jie, V Carter, A Hardjojo, JFM Van Boven and DB Price,
Respirology (Carlton, Vic.) , Apr 30 2019
Mixed inhaler device use for asthma is associated with worse inhaler technique and outcomes. Given that relievers are commonly prescribed as pressurized metred-dose inhalers (pMDI), changing preventers from dry powder inhalers (DPI) to pMDI may improve asthma outcomes. This study aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long-acting β2 -agonist combination therapy (ICS/LABA).This was a historical cohort study using Ajou University Hospital (Korea) patient records. Persistence of switch was defined as receiving ≥1 pMDI and no DPI after the switch. Effectiveness of switch was assessed as the proportion without severe asthma exacerbation and the proportion achieving risk domain asthma control (RDAC; no asthma-related hospitalization, antibiotics without upper respiratory diagnosis or acute course of oral corticosteroids) and overall asthma control (OAC; RDAC and ≤ 200 μg salbutamol/≤500 μg terbutaline average daily dose) comparing 1 year after and before the switch.Within 85 patients who switched from DPI to pMDI and persisted for a year, higher proportion were free from asthma exacerbation after the switch (mean difference in proportion = 0.129, 95% CI: 0.038-0.220). Switching to pMDI was also associated with better RDAC (75.3% vs 57.7%, P = 0.001) and OAC (57.7% vs 45.9%, P = 0.021). From the entire 117 patients who switched to fixed-dose combination (FDC)/ICS LABA pMDI, 76.1% (95% CI: 69.0-100.0%) patients persisted in the following 6 months.Switching to and persisting with pMDI was associated with decreased asthma exacerbations and improved asthma control. The majority of patients persisted with the switch to pMDI for ICS/LABA treatment.
Quantitative Evaluation of the Relationship between T-Wave-Based Features and Serum Potassium Level in Real-World Clinical Practice.
D Yoon, HS Lim, JC Jeong, TY Kim, JG Choi, JH Jang, E Jeong and CM Park,
BioMed research international , 2018
Proper management of hyperkalemia that leads to fatal cardiac arrhythmia has become more important because of the increased prevalence of hyperkalemia-prone diseases. Although T-wave changes in hyperkalemia are well known, their usefulness is debatable. We evaluated how well T-wave-based features of electrocardiograms (ECGs) are correlated with estimated serum potassium levels using ECG data from real-world clinical practice.We collected ECGs from a local ECG repository (MUSE™) from 1994 to 2017 and extracted the ECG waveforms. Of about 1 million reports, 124,238 were conducted within 5 minutes before or after blood collection for serum potassium estimation. We randomly selected 500 ECGs and two evaluators measured the amplitude (T-amp) and right slope of the T-wave (T-right slope) on five lead waveforms (V3, V4, V5, V6, and II). Linear correlations of T-amp, T-right slope, and their normalized feature (T-norm) with serum potassium levels were evaluated using Pearson correlation coefficient analysis.Pearson correlation coefficients for T-wave-based features with serum potassium between the two evaluators were 0.99 for T-amp and 0.97 for T-right slope. The coefficient for the association between T-amp, T-right slope, and T-norm, and serum potassium ranged from -0.22 to 0.02. In the normal ECG subgroup (normal ECG or otherwise normal ECG), there was no correlation between T-wave-based features and serum potassium level.T-wave-based features were not correlated with serum potassium level, and their use in real clinical practice is currently limited.
Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel.
E Quaquarini, D D'Ambrosio, F Sottotetti, F Gallivanone, M Hodolic, P Baiardi, R Palumbo, C Vellani, C Canevari, A Bernardo, I Castiglioni, C Porta and G Trifirò,
Contrast media & molecular imaging , 2019
The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of 18F-fluorocholine (18F-FCH) positron emission tomography (PET) parameters in mCRPC.Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent 18F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment 18F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUVmax, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body 18F-FCH PET indices were performed, and p < 0.05 was considered as significant.Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and 18F-FCH PET parameters were defined probably due to the small sample size.Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of 18F-FCH PET/CT imaging in clinical decision-making.
